In a report released today, Matthew Weston from UBS maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF248.00. The company’s shares opened today at $236.98.
According to TipRanks, Weston is a 4-star analyst with an average return of 13.9% and a 71.79% success rate.
In addition to UBS, Roche Holding AG also received a Hold from Berenberg Bank’s Luisa Hector in a report issued on April 11. However, on April 16, Morgan Stanley maintained a Sell rating on Roche Holding AG (Other OTC: RHHVF).
RHHVF market cap is currently $195.5B and has a P/E ratio of 15.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG (RHHVF) Company Description:
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Read More on RHHVF:
- Roche announces data from its Phase III OCARINA II study of OCREVUS
- Genentech reports data from OCARINA II study of Ocrevus
- Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
- Roche price target raised to CHF 260 from CHF 250 at Morgan Stanley
- Fresenius SE launches biosimilar of Roche’s Actemra
